The TB Diagnostics Critical Pathway is intended to be a virtual knowledge management tool to document a  TB diagnostic innovator's path to the rapid introduction and widespread scale-up of promising new TB tools, indicating the critical activities, stakeholders and resources along the pathway.

This tool was developed based on the collective input from a breadth of TB and global health stakeholders, as a resource for diagnostic developers and wider TB community.

This website is currently a beta version, and we welcome your comments and ideas for improvement!

Partners Behind the Pathway


The Foundation for Innovative New Diagnostics, or FIND, is an international non-profit organization that enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola.

FIND acts as a bridge between experts in technology development, policy and clinical care, reducing barriers to innovation and effective implementation of diagnostic solutions in low- and middle-income countries.

McGill International TB Centre

The McGill International TB Centre, situated at the McGill University Health Centre in Montreal, Canada, is a world leader in the interdisciplinary study of TB, bringing together researchers in biomedical, clinical, epidemiological and social determinants of TB and other mycobacterial diseases.

Stop TB Partnership

The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership's mission is to serve every person who is vulnerable to TB and ensure that high-quality diagnosis, treatment and care is available to all who need it. They operate through a secretariat hosted by UNOPS in Geneva, Switzerland and seven working groups whose role is to accelerate progress on access to TB diagnosis and treatment; research and development for new TB diagnostics, drugs and vaccines; and tackling drug resistant- and HIV-associated TB. The secretariat is governed by a Coordinating Board that sets strategic direction for the global fight against TB. The Partnership is recognized as a unique international body with the power to align actors all over the world in the fight against TB. The participation of a wide range of constituencies gives us credibility and the broad range of medical, social and financial expertises needed to defeat TB.


Unitaid is an international organisation that invests in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively. Unitaid is a hosted partnership of the World Health Organization (WHO). Unitaid researches and identifies new health solutions with potential to alleviate the burden of HIV/AIDS, tuberculosis and malaria. Through calls for proposals, they find partners best qualified to put key innovations into practice. These partners receive grants from Unitaid to fast-track access and reduce costs of more effective medicines, technologies and systems. In this way, Unitaid’s investments establish the viability of health innovations, allowing partner organisations to make them widely available.


The World Health Organization (WHO) is the directing and coordinating authority on international health within the United Nations’ system. Among the many areas of work, WHO's efforts in TB diagnostics include: Target product profile development and consensus building among stakeholders; industry engagement at early stages of development with guidance on preliminary assessment; study design and evaluation protocols for new technologies; commissioning systematic reviews of available studies for WHO review; GRADE evaluation of new diagnostics for potential endorsement; and supporting country adoption and dissemination of guidance on different technologies.


We would like to acknowledge the important contributions and feedback from the TB community and global health organizations around the world.

Anita Suresh
Senior Technology & Business Development Officer
Caroline Vadnais
Research Manager, RI-MUHC
Jacqueline Huh
Team Leader, Strategic Initiatives & Innovative Financing
Chris Gilpin
Claudia Denkinger
Draurio Barreira Cravo Neto
Sahu Suvanand
Sara Padidar